Gerald Chi, MD

Title: Research Fellow
Company: Beth Israel Deaconess Medical Center, Harvard Medical School
Location: Boston, Massachusetts, United States

Gerald Chi, MD Research Fellow at Beth Israel Deaconess Medical Center and Harvard Medical School, has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in the health care industry.

Receiving his medical degree in Taiwan in 2007, Dr. Chi always had a passion for research, believing that while physicians save one life at a time, researchers can develop more effective treatment for diseases, thereby saving millions of lives at a time. Upon relocating to the United States, he fell under the tutelage of Professor Michael Gibson, who taught Dr. Chi the skills he currently uses on a regular basis. Throughout his career, he is proud to have led several studies that have changed clinical practice and modified guideline recommendations with such organizations as the American Heart Association and the European Society of Cardiology.

Dr. Chi commenced his career in 2013 in a number of roles, including as a research fellow with Beth Israel Deaconess Medical Center, director of the WikiDoc Fellowship Program with WikiDoc Foundation, director of the PERFUSE Angiographic Core Laboratory with the PERFUSE Study Group, and biostatistician with the division of cardiovascular medicine at Beth Israel Deaconess Medical Center. Since 2016, he has also been a consultant with Portola Pharmaceuticals, Inc., and with the Baim Institute for Clinical Research since 2017.

A respected voice in the industry, Dr. Chi finds that reading outside of the health care field can further contribute to the understanding of his research as it provides a wider range of perspectives which can be applied to his studies. Alongside his primary endeavors, he holds the roles of editorial board member for several professional journals and contributor of articles to peer-reviewed journals. Looking toward the future, he aspires to conduct more multicenter randomized controlled trials, focusing on atrial fibrillation, thus saving the lives of more individuals suffering from cardiac disorders.

For more:


Google Scholar


Contact Dr. Chi

Leave a Reply